The chief financial officer (CFO) of Sigma Pharmaceuticals, Mark Smith, has resigned from the drugs maker and distributor to pursue other interests. His resignation is effective immediately. KPMG partner Mark Watson will act as CFO until the Sigma board has appointed a replacement. Sigma has advised that the search for a replacement is underway.
Smith’s resignation comes a month after Sigma’s chief executive, Elmo de Alwis, quit the company, following its AU$390m loss in the 2010 fiscal year. Sigma shares dropped over 48% following that result. Following Smith’s resignation, the company’s share price has fallen 2.7%.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.